LIDDS AB (publ)
STO: LIDDS.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mats Bjorn Wiking
- Employees
- 1
- Headquarters
- Uppsala, Sweden
- IPO year
- 2014
- Market cap
- SEK 3.4M
- Website
- https://www.liddspharma.com
Loading LIDDS…
Loading profile data…Frequently asked questions about LIDDS
What does LIDDS AB (publ) (LIDDS.ST) do?
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STIN...
Where does LIDDS.ST trade?
LIDDS AB (publ) (LIDDS.ST) trades on the Stockholm Stock Exchange.
What sector is LIDDS.ST in?
LIDDS AB (publ) (LIDDS.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of LIDDS AB (publ)?
Mats Bjorn Wiking is the chief executive officer of LIDDS AB (publ) (LIDDS.ST).
Where is LIDDS AB (publ) headquartered?
LIDDS AB (publ) is headquartered in Sweden.
Does LIDDS.ST pay a dividend?
LIDDS AB (publ) (LIDDS.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LIDDS.ST go public?
LIDDS AB (publ) (LIDDS.ST) completed its initial public offering in 2014.